Aim Rule 26
The following information is disclosed in accordance with Rule 26 of the AIM Rules.
These requirements were last reviewed and updated by the company on 30 May 2022.
Description of the Business
BiVictriX Therapeutics was formed in 2016 and is a rapidly emerging biotechnology company based in the UK. The company focuses on the development of next generation cancer therapies. Read More
Incorporation and Registered Office
BiVictriX Therapeutics Plc is incorporated in England & Wales with registered number 13470690 and registered address of Co Slater Heelis Limited, 86 Deansgate, Manchester, M3 2ER
BiVixtriX's main company of operation is the UK.
Iain Ross (Non-Executive Chairman)
Tiffany Daniels-Thorn (CEO)
Drummond Paris (Senior Independent Non-Executive Director)
Robert Hawkins (Independent Non-Executive Director)
Susan Lowther (Independent Non-Executive Director)
Dr. Michael Kauffman (Independent Non-Executive Director)
View Directors Biographies
Nominated Advisor and Joint Broker
SP Angel Corporate Finance LLP
Prince Frederick House
35-39 Maddox Street
Panmure Gordon & Co
One New Change
Acceleris Capital Limited
CT3, Wigan Investment Centre
55 Ludgate Hill
Financial Communications Advisor
Consilium Strategic Communications
85 Gresham Street
Slater Heelis Limited
Share Registrars Limited
17 West Street
Articles of Association - View Here
Admission Document - View Here
Company Announcements - View Here
Company Presentations - View Here
Financial Reports - View Here
The Company is subject to the UK City Code on Takeovers and Mergers.
The Board seeks to follow best practice in corporate governance appropriate with the size and regulatory framework that applies to AIM companies. The Board reviews and applies the principles and provisions of the 2018 Quoted Company Alliance Corporate Governance Code (“Code”) where it is appropriate to do so to support the governance framework.
View more information on corporate governance here
BivictriX is listed solely on the AIM market of the London Stock Exchange. The Company is not listed on any other Exchanges or Trading Platforms.
There are no restrictions on the transfer of securities.
Shares & Significant Shareholders
Total Number of Shares in Issue: 66,115,201 ordinary shares of 1 pence each
Shares Not in Public Hands: 21.3%
Shareholders with 3% or more of the total issued share capital:
Number of Shares which could be acquired under financial instruments or similar
Percentage of Issued Share Capital
Development Bank of Wales
Alderly Park Ventures